Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 2760 publications.

Brogan A. Advancing accuracy and transparency in health economic evaluation. Presentation to be given at the ISPOR 2025; May 16, 2025. Montreal, Canada.

Davis AE, Blake M, Lehoucq M, Brogan AJ, McDade C, Carlson KB, Lopman B, Buck PO. Estimates of the public health impact of norovirus vaccination for older adults in the United States. Poster to be given at the ISPOR 2025; May 16, 2025. Montréal, Canada.

La E, Singer D, Dubois de Gennes C, Graham J, Grace M, Poston S, Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged 60 years with cardiopulmonary disease. Poster to be given at the ISPOR 2025; May 15, 2025. Montreal, Canada.

Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Estimated public health impact of adjuvanted RSVPreF3 vaccination in US adults aged 18-49 years who are at increased risk for severe RSV disease. Poster to be given at the ISPOR 2025; May 15, 2025. Montreal, Canada.

Brogan A, Zhang K. From data to dialogue: mastering conversations to amplify HEOR impact and influence. Presentation to be given at the ISPOR 2025; May 15, 2025. Montreal, Canada.

Cha-Silva AS, Zhang KH, Graham C, Kurosky SK, Tran H, Law EH, Song EJ. A cost per responder analysis of ritlecitinib and baricitinib: assessing the impact of clinical efficacy and dosing variability on overall treatment costs of severe Alopecia Areata (AA). Poster to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Riemer J, Campbell K, Arthurs E, Knight C. Cost-effectiveness of belimumab for the treatment of adults with active lupus nephritis in Canada. Presentation to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Herring WL, Coon C, Lenderking W, Whittington M. Rethinking clinical meaningfulness and value assessment in the context of chronic progressive diseases. Presentation to be given at the ISPOR 2025; May 15, 2025. Montréal, Canada.

Marcano Belisario J, Lunan M, Hawe E, Farrelly G. Evaluation of machine learning assisted title and abstract screening in 5 clinical systematic literature reviews. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Marcano Belisario J, Hartley L, Phan NTN, Mugwagwa T, Tingir N. Economic systematic literature of nirmatrelvir+ritonavir for the treatment of patients with mild to moderate COVID-19. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Earnshaw S, McDade C, Dodoo C, Huynh Z, Zhang K, Chang SN. Economic impact of multiplex point-of-care testing for chlamydia trachomatis, neisseria gonorrhoeae, and mycoplasma genitalium: development of a modeling framework. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Pizzi L, Earnshaw S, Blanchette C, Thompson D. Climbing the HEOR career ladder: strategies for success in an era of change. Presentation to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Dellon ES, Goodwin B, Liu E, de los Santos B, Korgaonkar S, Meyers J, Schaeffer-Koziol CR, Terreri B, Shah ED. Eosinophilic esophagitis-related healthcare resource utilization and associated costs for payers and patients: a retrospective cohort study of US health insurance claims data. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Clay B, Pop-Busui R, Januzzi JL, Neveux P, Zhang K, McDade C, Earnshaw S. Economic evaluation of NT-proBNP testing to facilitate prevention of heart failure in adults with type 2 diabetes. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Chang M, Peters B, Ronquest N, Lucas A, Zhang Y, Simpson M, Shelley K. Assessing the budget impact and time savings of introducing nivolumab and hyaluronidase SC to patients receiving nivolumab IV across multiple indications on a US healthcare plan. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Ronquest N, Zhang Y, Mladsi D. Assessing the impact of the United States (US) Inflation Reduction Act (IRA) regulations on investment incentives for orphan disease drug development. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The annual economic burden of RSV in high-risk US adults aged 18-59: a modeling study. Poster to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada.

Hicks K, Xiao Z, Paret K, del Pilar Martin Matos M, Joshi K, Ghaswalla P. The potential public health and economic benefit of an mRNA-based RSV vaccine, mRNA-1345, among high-risk adults aged 18-59 years in the US: a modeling study. Poster to be given at the ISPOR 2025; May 13, 2025. Montréal, Canada.

Leber B, Ruiz MT, Elgendy H, Pettersson F, Prebet T, Vigil CE, Parikh RC, Korgaonkar S, Bello F, Davis KL, Gaugler L, Strocchia M, Sieluk J, Li Y, Schuh AC. Real-world treatment patterns and outcomes with oral azacitidine maintenance therapy in patients with acute myeloid leukemia. Cancer. 2025 Apr 15;131(8):e35845. doi: 10.1002/cncr.35845

La EM, Sweeney C, Davenport E, Bunniran S. Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults. Vaccine. 2025 Apr 8;54:127057. doi: 10.1016/j.vaccine.2025.127057

La EM, Sweeney C, Davenport E, Calhoun S, Harmelink A, Singer D. Healthcare professionals' knowledge, attitudes, and practices regarding respiratory syncytial virus disease and vaccination in adults aged 60 years and older. Infect Dis Ther. 2025 Apr;14(4):735-52. doi: 10.1007/s40121-025-01119-0

Craig T, Baptist AP, Anderson J, Zaragoza-Urdaz RH, Burnette AF, Kelbel TE, Riedl MA, Vanegas A, Boyle K, Bartsch JL, Darden C, Brown TM, Schultz BG, Blair C, Sing K, Fox D, Juethner S. Hereditary angioedema: patient health care experiences within underrepresented racial and ethnic groups in the United States. Ann Allergy Asthma Immunol. 2025 Apr;134(4):465-473.e. doi: 10.1016/j.anai.2025.01.007

Handels R, Herring WL, Grimm S, Skoldunger A, Winblad B, Wimo A, Jonsson L. New IPECAD open-source model framework for the health technology assessment of early Alzheimer's disease treatment: development and use cases. Value Health. 2025 Apr;28(4):511-8. doi: 10.1016/j.jval.2024.07.009

Handels R, Herring WL, Kamgar F, Aye S, Tate A, Green C, Gustavsson A, Wimo A, Winblad B, Skoldunger A, Raket LL, Stellick CB, Spackman E, Hlavka J, Wei Y, Mar J, Soto-Gordoa M, de Kok I, Bruck C, Anderson R, Pemberton-Ross P, Urbich M, Jonsson L. IPECAD Modeling Workshop 2023 cross comparison challenge on cost-effectiveness models in Alzheimer's disease. Value Health. 2025 Apr;28(4):497-510. doi: 10.1016/j.jval.2024.09.006

Nahas SJ, Zhao Y, Graham CN, Erbe A, Blumenfeld A. Comparative efficacy of AXS-07 vs. gepants for acute treatment of migraine: a network meta-analysis. Poster presented at the American Academy of Neurology (AAN) 2025 Annual Meeting; April 2025.

Brufsky AM, Sandin R, Stergiopoulos S, Chen C, Karanth S, Li B, Esterberg E, Makari D, Candrilli SD, Goyal RK, Rugo HS. Overall survival with palbociclib and aromatase inhibitor versus aromatase inhibitor alone in older patients with HR+/HER2− metastatic breast cancer. Cancer Med. 2025 Apr;14(7):e70719. doi: 10.1002/cam4.70719

Vickers AD. A comparison of the performance of 6 surrogacy models, including weighted linear regression, meta-regression, and bivariate meta-analysis. Value Health. 2025 Apr;28(4):591-8. doi: 10.1016/j.jval.2025.01.005

Paret K, Chaiyakunapruk N, Ronquest N, Pearson I. Introduction to best practices for country adaptations of economic models - virtual. Presented at the 2025 Virtual ISPOR Short Course Program; March 26, 2025. Previously presented at the 2024 Virtual ISPOR Short Course Program.

Wilson MR, Castaman G, Thomas W, Millar CM, Escolar G, Miesbach WA, McDade CL, Tomic R, Yan S. Cost-effectiveness of voncento prophylaxis versus on-demand treatment in von willebrand disease in the United Kingdom. Blood Adv. 2025 Mar 25;9(6):1312-9. doi: 10.1182/bloodadvances.2024014376

Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Modeled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years at increased risk for severe RSV disease in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.

Verelst F, La E, Singer D, Graham J, Grace M, Biundo E, Poston S. Modelled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 60 years and older in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.

Shah HA, Jutlla G, Herrera-Restrepo O, Graham J, Grace M, Khan SA, Kuylen E, Begum S, Verelst F, Kocaata Z. Market and non-market productivity losses associated with invasive meningococcal disease in the USA. Pharmacoeconomics. 2025 Mar 12. doi: 10.1007/s40273-025-01477-0

Weber J, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, van Akkooi ACJ, Menzies AM, Long GV, Taylor AM, Haanen J, Zijlker LP, Davis KL, Karanth S, Norton D, Connolly L. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma. Oncologist. 2025 Mar 10;30(3):oyae289. doi: 10.1093/oncolo/oyae289

Megias-Vericat JE, Escolar G, Wilson MR, Mendez P, McDade CL, Barrientos LV, Tomic R, Panebianco M, Linden S, Yan S. Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain. J Med Econ. 2025 Mar 7;28(1):436-45. doi: 10.1080/13696998.2025.2474886

Silver SM, Houghton K, Hitchens A, Ansquer VD, Ciepielewska M. Real-world assessment of the patient profile, clinical characteristics, treatment patterns, and outcomes associated with erythropoietic and X-linked protoporphyria. J Dermatol. 2025 Mar;52(3):416-22. doi: 10.1111/1346-8138.17607

Shah HA, Jutlla G, Herrera-Restrepo O, Graham J, Hicks KA, Carrico J, Grace M, Clements DE, Burman C, Sohn WY, Kuylen E, Begum S, Kocaata Z. Public health impact of introducing a pentavalent vaccine against invasive meningococcal disease in the United States. Pharmacoeconomics. 2025 Mar;43(3):311-29. doi: 10.1007/s40273-024-01439-y

Greenhawt M, Bansal P, Goodwin B, Korgaonkar S, Liu Y, Meyers J, Shah E, Terreri B, Dellon E, Schaeffer-Koziol C. High incidence and prevalence of eosinophilic esophagitis in the USA identified: an analysis of US health insurance claims data. Poster presented at the 2025 American Academy of Allergy Asthma & Immunology (AAAAI)/WAO Joint Congress; February 28, 2025. San Diego, CA.

Pritchard C, Kutikova L, Pitman R, Lai KZH, Beyhaghi H, Gibbons I, Erbe A, Zivkovic-Gojovic M, Cosgrove C, Sculpher M, Salisbury D. Cost-effectiveness of introducing nuvaxovid to COVID-19 vaccination in the United Kingdom: a dynamic transmission model. Vaccines (Basel). 2025 Feb 14;13(2):187. doi: 10.3390/vaccines13020187

Viguerie A, O'Shea J, Johnston M, Schreiber D, Adams J, Bates L, Carrico J, Hicks KA, Lyles CM, Farnham PG. Impact of increased uptake of long-acting injectable antiretroviral therapy on HIV incidence and viral suppression in the United States under 2021 FDA guidelines. AIDS. 2025 Feb 5. doi: 10.1097/QAD.0000000000004144

Passamonti F, Korgaonkar S, Parikh RC, Chevli M, Yucel A, Rombi J, Jones S, Zissler D, Davis KL, Slaff S. Real-world treatment patterns and health outcomes for patients with myelofibrosis treated with fedratinib. Future Oncol. 2025 Feb;21(5):579-91. doi: 10.1080/14796694.2025.2454895

Gold BD, Goodwin B, Davis K, Sweeney C, Ziemiecki R, Jiang J, Fan T, Boules M, Chen ST, Katzka DA. Satisfaction with and adherence to off-label corticosteroids in adolescents and adults with eosinophilic esophagitis: results of a web-based survey in the United States. J Clin Gastroenterol. 2025 Feb;59(2):138-46. doi: 10.1097/MCG.0000000000002006

Patel JN, Chaihorsky L, Dong OM, Lu CY, Moretz C, Reese E, Teeple W, Brown B, Rogers S. Medical policy determinations for pharmacogenetic tests among US health plans. Am J Manag Care. 2025 Feb 1;31(2):e47-55. doi: 10.37765/ajmc.2025.89683

Ahn JH, da Silva Pedrosa M, Lopez LR, Tibbs TN, Jeyachandran JN, Vignieri EE, Rothemich A, Cumming I, Irmscher AD, Haswell CJ, Zamboni WC, Yu YA, Ellermann M, Denson LA, Arthur JC. Intestinal E. coli-produced yersiniabactin promotes profibrotic macrophages in Crohn's disease. Cell Host Microbe. 2025 Jan 8;33(1):71-88.e9. doi: 10.1016/j.chom.2024.11.012

Ollendorf D, Tsiao E, Whittington M, Ronquest N. Role of economic evaluations in value assessments for pharmaceutical interventions in the United States. Presented at the ISPOR Education Center Online Learning; 2025.

Halsby K, Dobler G, Easton A, Karelis G, Krbkova L, Kyncl J, Sellner J, Strle F, Veje M, Zajkowska J, Zavadska D, Angulo FJ, Pilz A, Erber W, Gabriel M, Russo J, Price M, Madhava H, Meyding-Lamade UK. Evaluating the need for standardised disease manifestation categories in patients infected with the tick-borne encephalitis virus: a Delphi panel. Ticks Tick Borne Dis. 2025 Jan;16(1):102431. doi: 10.1016/j.ttbdis.2024.102431

La EM, Graham J, Singer D, Molnar D, Poston S, Curran D, Pickett J, Verelst F. Cost-effectiveness of the adjuvanted RSVPreF3 vaccine among adults aged ≥60 years in the United States. Hum Vaccin Immunother. 2024 Dec 31;20(1):2432745. doi: 10.1080/21645515.2024.2432745

Perdrizet J, Wilson M, Wannaadisai W, Apodaca K, Grant L. Pneumococcal serotypes missing prespecified efficacy threshold in immunogenicity trials: real-world evidence from national immunization programs. Expert Rev Vaccines. 2024 Dec 31;23(1):879-86. doi: 10.1080/14760584.2024.2409662

Eiden AL, Hartley L, Garbinsky D, Saande C, Russo J, Gabriel MH, Price M, Bhatti A. Adult vaccination coverage in the United States: a database analysis and literature review of improvement strategies. Hum Vaccin Immunother. 2024 Dec 31;20(1):2381283. doi: 10.1080/21645515.2024.2381283

Cappellini MD, Glassberg MB, Meyers J, Jimenez M, Nham T, Bueno L, Sieluk J, Yucel A, Alashkar F. Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study. Ther Adv Hematol. 2024 Dec 15;15. doi: 0.1177/20406207241298088

Shadman M, Roeker L, Pinilla-Ibarz J, Srivastava B, Karve S, Krigsfeld GS, Franceschini E, Saifan C, Karanth S, Goyal RK, Rombi J, Stephens DM. Association between dose reduction and duration of therapy in patients receiving ibrutinib or acalabrutinib for chronic lymphocytic leukemia: a medical chart review study. Poster presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition; December 8, 2024. San Diego, California.